Prime Therapeutics LLC (Prime) announces it has earned URAC accreditation in Pharmacy Benefit Management (PBM). Read More »

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced the launch of a generic version of Delzicol®1 (mesalamine) delayed-release capsules, 400 mg, in the U.S. Read More »

All 140 CVS Pharmacy locations in Minnesota area now using time-delay safe technology Read More »

Abbott (NYSE: ABT) announced that m-PIMA™ HIV-1/2 VL, the world's first point-of-care viral load diagnostic test, has received the World Health Organization's Prequalification approval (WHO PQ). Read More »

Safe Rx announced its availability in California Kaiser Permanente pharmacies. Read More »

AmerisourceBergen issued the following announcement on April 24.Original source can be found here. Read More »

Rapha Capital Management, LLC (https://www.raphacap.com), an investment management firm located in Miami, Florida, and their associated entities announced their participation in a Series C financing for Poseida Therapeutics ("Poseida"). Read More »

Dr. Annabelle Manalo on Wednesday and Today met over 400 members of the Pharmacy Society of Wisconsin including each of its board members of the Pharmacy Society of Wisconsin. Read More »

Nationwide demand for local pharmacy model fuels expansion Read More »

Within a week of FDA approval, MAVENCLAD has formulary coverage with one of the leading pharmacy benefit managers in the U.S. Read More »

Large, randomized ALPINE trial showed both long-acting injectable medications effectively controlled schizophrenia symptoms throughout six-month study Read More »

In Honor of April's IBS Awareness Month, Efforts Highlight Advances in Research Read More »

New safes for controlled substances will help combat opioid epidemic in the state and reduce robbery incidents Read More »

Review follows rapid growth in product portfolio Read More »

Safe Rx announced its availability in selected California locations of The Medicine Shoppes, a leading franchised pharmacy store banner. Read More »

Sunosi is the first and only dual-acting dopamine and norepinephrine reuptake inhibitor approved by the FDA to improve wakefulness in adults living with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea Read More »

Xynomic Pharmaceuticals, Inc. ("Xynomic"), a clinical stage US-China oncology drug development company, and Bison Capital Acquisition Corporation (Nasdaq: BCAC), jointly announced that Xynomic and its collaborators will present at the American Society of Clinical Oncology ("ASCO") 2019 Annual Meeting to be held in Chicago from May 31, 2019 - June 4, 2019. Read More »

New data presented and simultaneously published in the Journal of the American College of Cardiology show treatment with MitraClip resulted in significant and sustained long-term quality-of-life improvements compared to medical therapy Read More »

Partnership to raise awareness of the increased burden of heart failure in African Americans and shed light on approaches to managing the unique challenges facing this patient community Read More »

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) presented new Phase 2 data from its investigative drug candidates etrasimod, a next-generation, oral, selective sphingosine 1 phosphate (S1P) receptor modulator in development for the treatment of moderate to severely active ulcerative colitis (UC), and olorinab, a peripherally restricted, highly selective, full agonist of the cannabinoid receptor type 2 (CB2) in development for the treatment of visceral pain associated with gastrointestinal (GI) diseases, at the 14th Congress of European Crohn's and Colitis Organisation (ECCO). Read More »